6-O-α-D-Maltosyl-β-cyclodextrin - CAS 104723-60-6
Catalog number: 104723-60-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C54H90O45
Molecular Weight:
1459.27
COA:
Inquire
Targets:
Others
Description:
6-O-α-D-Maltosyl-β-cyclodextrin is a cellular cholesterol modifier which can form soluble inclusion complex with cholesterol and is much less cytotoxic to human erythrocytes and Caco-2 cells.
Purity:
>98%
MSDS:
Inquire
InChIKey:
QFSFPJHBIGWPMD-PBVGKYIBSA-N
InChI:
InChI=1S/C54H90O45/c55-1-10-19(63)20(64)29(73)47(83-10)92-38-11(2-56)84-46(30(74)21(38)65)82-9-18-45-28(72)37(81)54(91-18)98-44-17(8-62)89-52(35(79)26(44)70)96-42-15(6-60)87-50(33(77)24(42)68)94-40-13(4-58)85-48(31(75)22(40)66)93-39-12(3-57)86-49(32(76)23(39)67)95-41-14(5-59)88-51(34(78)25(41)69)97-43-16(7-61)90-53(99-45)36(80)27(43)71/h10-81H,1-9H2/t10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20+,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46+,47-,48?,49-,50-,51-,52-,53-,54-/m1/s1
Canonical SMILES:
C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OCC3C4C(C(C(O3)OC5C(OC(C(C5O)O)OC6C(OC(C(C6O)O)OC7C(OC(C(C7O)O)OC8C(OC(C(C8O)O)OC9C(OC(C(C9O)O)OC1C(OC(O4)C(C1O)O)CO)CO)CO)CO)CO)CO)O)O)CO)O)O)O)O
1.Complex of branched cyclodextrin and lidocaine prolonged the duration of peripheral nerve block.
Suzuki R1, Arai YC, Hamayasu K, Fujita K, Hara K, Yamaguchi T, Sasaguri S. J Anesth. 2009;23(2):295-7. doi: 10.1007/s00540-008-0720-5. Epub 2009 May 15.
Although laboratories have tried to synthesize new local anesthetics, currently available local anesthetics rarely provide prolonged regional blockade. New models of sustained-release preparations of local anesthetics with liposomes and microspheres have been studied to prolong the duration of the effects of the local anesthetics. In the present study, we examined whether a complex of a branched cyclodextrin (CD), 6-O-alpha-D-maltosyl-beta-cyclodextrin (G2-beta-CD) and lidocaine could prolong local nerve block when compared with plain lidocaine. The sciatic nerve in male Sprague-Dawley rats was blocked with plain lidocaine (n = 10), the complex of G2-beta-CD + lidocaine (n = 10), or plain G2-beta-CD (n = 4). Sensory block was assessed with a hotplate set at 56 degrees C. The median duration of the block was longer in the complex group than in the plain lidocaine group (110 min; range, 70-150 min vs 55 min; range, 40-80 min; P < 0.05), thus demonstrating that the complex with CyD significantly prolonged the nerve block effect of lidocaine.
2.Experimental and Theoretical Investigations on the Supermolecular Structure of Isoliquiritigenin and 6-O-α-D-Maltosyl-β-cyclodextrin Inclusion Complex.
Li B1, Liu B2, Li J3, Xiao H4, Wang J5, Liang G6. Int J Mol Sci. 2015 Aug 4;16(8):17999-8017. doi: 10.3390/ijms160817999.
Isoliquiritigenin (ILTG) possesses many pharmacological properties. However, its poor solubility and stability in water hinders its wide applications. The solubility of bioactive compounds can often be enhanced through preparation and delivery of various cyclodextrin (CD) inclusion complexes. The 6-O-α-D-maltosyl-β-CD (G2-β-CD), as one of the newest developments of CDs, has high aqueous solubility and low toxicity, especially stable inclusion characteristics with bioactive compounds. In this work, we for the first time construct and characterize the supermolecular structure of ILTG/G2-β-CD by scanning electron microscopy (SEM), ultraviolet-visible spectroscopy (UV), Fourier transform infrared spectroscopy (FT-IR), and X-ray diffractometry (XRD). The solubility of ILTG in water at 25 °C rises from 0.003 to 0.717 mg/mL by the encapsulation with G2-β-CD. Our experimental observations on the presence of the ILTG/G2-β-CD inclusion complex are further supported by the ONIOM(our Own N-layer Integrated Orbital molecular Mechanics)-based QM/MM (Quantum Mechanics/Molecular Mechanics) calculations, typically substantiating these supermolecular characteristics, such as detailed structural assignments, preferred binding orientations, selectivity, solvent effects, interaction energies and forces of the ILTG/G2-β-CD inclusion complex.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 103213-49-6 [Glu1]-Fibrinopeptide B human

[Glu1]-Fibrinopeptide B human
(CAS: 103213-49-6)

[Glu1]-Fibrinopeptide B, generated from fibrinopeptide B amino acid residues 1-14, is used as a mass spec (MS) standard in proteomic research.

CAS 1953-02-2 Tiopronin

Tiopronin
(CAS: 1953-02-2)

Tiopronin is a US Food and Drug Administration (FDA)-approved drug for the treatment of cystinuria by controlling the rate of cystine precipitation and excretio...

CAS 135202-79-8 Ilonidap

Ilonidap
(CAS: 135202-79-8)

Ilonidap is an anti-Inflammatory agent. No detailed information has been published yet.

CAS 93565-01-6 MDL 72527

MDL 72527
(CAS: 93565-01-6)

MDL 72527 is a polyamine oxidase inhibitor. It can block the production of H2O2 and increase the cells survival. MDL 72527 shows anticancer and neuroprotective ...

LY-113174
(CAS: 112959-07-6)

LY-113174 is a novel class of nonsteroidal aromatase inhibitor. It may prove useful in the treatment of estrogen-dependent diseases.

T7 Tag Peptide

T7 Tag Peptide, an epitope tag composed of an 11-residue peptide encoded from the leader sequence of the T7 bacteriophage gene10, and serves as a tag in many ex...

CAS 552292-08-7 Rolapitant

Rolapitant
(CAS: 552292-08-7)

Rolapitant is a selective NK1 receptor antagonist (antagonist for the NK1 receptor).

CAS 89250-26-0 Astragalus polysaccharide

Astragalus polysaccharide
(CAS: 89250-26-0)

Astragalus polysaccharide is one kind of biological macromolecule extracted from Astragalus. It has antiviral activities.

Chemical Structure

CAS 104723-60-6 6-O-α-D-Maltosyl-β-cyclodextrin

Quick Inquiry

Verification code

Featured Items